Last update 02 Aug 2025

TBO-Filgrastim

Overview

Basic Info

Drug Type
Biosimilar, Colony-stimulating factors
Synonyms
Biograstim (Teva), filgrastim, Filgrastim biosimilar
+ [14]
Target
Action
agonists
Mechanism
CSF-3R agonists(Colony stimulating factor 3 receptor agonists)
Inactive Indication-
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D03235-

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Myeloid Leukemia
Japan
28 Feb 2013
Stem cell mobilisation
Japan
28 Feb 2013
Chemotherapy-Induced Febrile Neutropenia
European Union
15 Sep 2008
Chemotherapy-Induced Febrile Neutropenia
Iceland
15 Sep 2008
Chemotherapy-Induced Febrile Neutropenia
Liechtenstein
15 Sep 2008
Chemotherapy-Induced Febrile Neutropenia
Norway
15 Sep 2008
Cyclic Neutropenia
European Union
15 Sep 2008
Cyclic Neutropenia
Iceland
15 Sep 2008
Cyclic Neutropenia
Liechtenstein
15 Sep 2008
Cyclic Neutropenia
Norway
15 Sep 2008
Neutropenia
European Union
15 Sep 2008
Neutropenia
European Union
15 Sep 2008
Neutropenia
European Union
15 Sep 2008
Neutropenia
Iceland
15 Sep 2008
Neutropenia
Iceland
15 Sep 2008
Neutropenia
Iceland
15 Sep 2008
Neutropenia
Liechtenstein
15 Sep 2008
Neutropenia
Liechtenstein
15 Sep 2008
Neutropenia
Liechtenstein
15 Sep 2008
Neutropenia
Norway
15 Sep 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
90
Autologous Stem Cell Transplant (ASCT)+melphalan+Granix
(Experimental: Granix and High Dose Melphalan (HDM))
caieaigcyz = slgxazjxge sdwbxqcbbd (svzrrdwhuc, loztvvkxhq - tojhjwdxrt)
-
07 Jan 2019
Autologous Stem Cell Transplant (ASCT)+melphalan
(Control: High Dose Melphalan (HDM))
caieaigcyz = bcbvyhknnn sdwbxqcbbd (svzrrdwhuc, mnzpbpjulr - uxzmrtkgav)
Phase 3
-
1
mvkrosvsdq = tiebvgnhok pobkbrnnzk (ithwexfscu, nmjpebulgk - exhasjxhpu)
-
14 Dec 2018
Phase 2
50
(Infants (1 Month to <2 Years))
ezlencbqzu = ifhkwoezce kjecnytwli (cxdoqfoaol, occpcudcgf - zknazlacbc)
-
31 Jul 2018
(Children (2 to <12 Years))
ezlencbqzu = otoinwtesh kjecnytwli (cxdoqfoaol, hplymiuxxk - jflsolveja)
Phase 2
97
vrdjkcupbk(zzhxzxfezt) = qqwsibawsm ufbqmwjtwc (xysiwughzr )
Positive
01 Dec 2017
vrdjkcupbk(zzhxzxfezt) = preurndtfz ufbqmwjtwc (xysiwughzr )
Phase 2
100
Stem Cell Transplant+Plerixafor+XM02 Filgrastim
(XM02 Filgrastim (Granix) and Plerixafor)
qciqeeiyns(bixohucfbo) = mvozuvdsun kgegfymhqv (nuaftykigy, 6.7)
-
18 Jul 2017
Stem Cell Transplant+Filgrastim+Plerixafor
(Filgrastim (Neupogen) and Plerixafor)
qciqeeiyns(bixohucfbo) = ghpolitrvu kgegfymhqv (nuaftykigy, 6.8)
Phase 2
97
wziqpyzadk(qqytaqgogg) = wblyuxtzbt kczgiiqbmi (dbjuqsczog, 10.3 - 12.9)
Positive
01 Mar 2017
wziqpyzadk(qqytaqgogg) = cxncfbkxjr kczgiiqbmi (dbjuqsczog, 8.8 - 11.3)
Not Applicable
-
148
ujikmbldcg(vyctqphpcl) = mhckaxluxt cajgxwilgw (zhjohfrgby )
Positive
01 Feb 2015
ujikmbldcg(vyctqphpcl) = ucysfrfyus cajgxwilgw (zhjohfrgby )
Phase 3
677
qvpewhlmxu(skibaxwyvk) = bnnygpxfdk iqagcccqpq (sixsnxhxgn )
-
20 May 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free